|
1
|
Hardie DG: The AMP-activated protein
kinase pathway - new players upstream and downstream. J Cell Sci.
117:5479–5487. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lizcano JM, Göransson O, Toth R, Deak M,
Morrice NA, Boudeau J, Hawley SA, Udd L, Mäkelä TP, Hardie DG, et
al: LKB1 is a master kinase that activates 13 kinases of the AMPK
subfamily, including MARK/PAR-1. EMBO J. 23:833–843. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lawlor MA and Alessi DR: PKB/Akt: A key
mediator of cell proliferation, survival and insulin responses? J
Cell Sci. 114:2903–2910. 2001.PubMed/NCBI
|
|
4
|
Calleja V, Laguerre M, Parker PJ and
Larijani B: Role of a novel PH-kinase domain interface in PKB/Akt
regulation: structural mechanism for allosteric inhibition. PLoS
Biol. 7:e172009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Calleja V, Alcor D, Laguerre M, Park J,
Vojnovic B, Hemmings BA, Downward J, Parker PJ and Larijani B:
Intramolecular and intermolecular interactions of protein kinase B
define its activation in vivo. PLoS Biol. 5:e952007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calleja V, Laguerre M and Larijani B: 3-D
structure and dynamics of protein kinase B-new mechanism for the
allosteric regulation of an AGC kinase. J Chem Biol. 2:11–25. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Staal SP: Molecular cloning of the akt
oncogene and its human homologues AKT1 and AKT2: Amplification of
AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci
USA. 84:5034–5037. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng JQ, Godwin AK, Bellacosa A, Taguchi
T, Franke TF, Hamilton TC, Tsichlis PN and Testa JR: AKT2, a
putative oncogene encoding a member of a subfamily of
protein-serine/threonine kinases, is amplified in human ovarian
carcinomas. Proc Natl Acad Sci USA. 89:9267–9271. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng JQ, Ruggeri B, Klein WM, Sonoda G,
Altomare DA, Watson DK and Testa JR: Amplification of AKT2 in human
pancreatic cells and inhibition of AKT2 expression and
tumorigenicity by antisense RNA. Proc Natl Acad Sci USA.
93:3636–3641. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stahl JM, Sharma A, Cheung M, Zimmerman M,
Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L and Robertson
GP: Deregulated Akt3 activity promotes development of malignant
melanoma. Cancer Res. 64:7002–7010. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stål O, Pérez-Tenorio G, Akerberg L,
Olsson B, Nordenskjöld B, Skoog L and Rutqvist LE: Akt kinases in
breast cancer and the results of adjuvant therapy. Breast Cancer
Res. 5:R37–R44. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu X, Sakon M, Nagano H, Hiraoka N,
Yamamoto H, Hayashi N, Dono K, Nakamori S, Umeshita K, Ito Y, et
al: Akt2 expression correlates with prognosis of human
hepatocellular carcinoma. Oncol Rep. 11:25–32. 2004.
|
|
13
|
Roy HK, Olusola Bf, Clemens DL, Karolski
WJ, Ratashak A, Lynch HT and Smyrk TC: AKT proto-oncogene
overexpression is an early event during sporadic colon
carcinogenesis. Carcinogenesis. 23:201–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakatani K, Thompson DA, Barthel A, Sakaue
H, Liu W, Weigel RJ and Roth RA: Up-regulation of Akt3 in estrogen
receptor-deficient breast cancers and androgen-independent prostate
cancer lines. J Biol Chem. 274:21528–21532. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Houseknecht KL and Spurlock ME: Leptin
regulation of lipid homeostasis: dietary and metabolic
implications. Nutr Res Rev. 16:83–96. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Myers MG Jr: Leptin receptor signaling and
the regulation of mammalian physiology. Recent Prog Horm Res.
59:287–304. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cirillo D, Rachiglio AM, la Montagna R,
Giordano A and Normanno N: Leptin signaling in breast cancer: An
overview. J Cell Biochem. 105:956–964. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
El-Masry OS, Brown BL and Dobson PR:
Effects of activation of AMPK on human breast cancer cell lines
with different genetic backgrounds. Oncol Lett. 3:224–228.
2012.PubMed/NCBI
|
|
19
|
Hardie DG and Alessi DR: LKB1 and AMPK and
the cancer-metabolism link - ten years after. BMC Biol. 11(36)2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brazil DP, Yang ZZ and Hemmings BA:
Advances in protein kinase B signalling: AKTion on multiple fronts.
Trends Biochem Sci. 29:233–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rattan R, Giri S, Singh AK and Singh I:
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits
cancer cell proliferation in vitro and in vivo via AMP-activated
protein kinase. J Biol Chem. 280:39582–39593. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kimball SR: Interaction between the
AMP-activated protein kinase and mTOR signaling pathways. Med Sci
Sports Exerc. 38:1958–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vazquez-Martin A, Oliveras-Ferraros C, del
Barco S, Martin-Castillo B and Menendez JA: The antidiabetic drug
metformin: a pharmaceutical AMPK activator to overcome breast
cancer resistance to HER2 inhibitors while decreasing risk of
cardiomyopathy. Ann Oncol. 20:592–595. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hadad SM, Fleming S and Thompson AM:
Targeting AMPK: a new therapeutic opportunity in breast cancer.
Crit Rev Oncol Hematol. 67:1–7. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sundaram S, Johnson AR and Makowski L:
Obesity, metabolism and the microenvironment: Links to cancer. J
Carcinog. 12(19)2013.PubMed/NCBI
|
|
26
|
Ando S and Catalano S: The multifactorial
role of leptin in driving the breast cancer microenvironment. Nat
Rev Endocrinol. 8:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Frankenberry KA, Skinner H, Somasundar P,
McFadden DW and Vona-Davis LC: Leptin receptor expression and cell
signaling in breast cancer. Int J Oncol. 28:985–993.
2006.PubMed/NCBI
|
|
28
|
Garofalo C and Surmacz E: Leptin and
cancer. J Cell Physiol. 207:12–22. 2006. View Article : Google Scholar
|
|
29
|
Okumura M, Yamamoto M, Sakuma H, Kojima T,
Maruyama T, Jamali M, Cooper DR and Yasuda K: Leptin and high
glucose stimulate cell proliferation in MCF-7 human breast cancer
cells: reciprocal involvement of PKC-alpha and PPAR expression.
Biochim Biophys Acta. 1592:107–116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Perera CN, Spalding HS, Mohammed SI and
Camarillo IG: Identification of proteins secreted from leptin
stimulated MCF-7 breast cancer cells: A dual proteomic approach.
Exp Biol Med (Maywood). 233:708–720. 2008. View Article : Google Scholar
|
|
31
|
Nkhata KJ, Ray A, Schuster TF, Grossmann
ME and Cleary MP: Effects of adiponectin and leptin co-treatment on
human breast cancer cell growth. Oncol Rep. 21:1611–1619.
2009.PubMed/NCBI
|
|
32
|
Park J and Scherer PE: Leptin and cancer:
from cancer stem cells to metastasis. Endocr Relat Cancer.
18:C25–C29. 2011. View Article : Google Scholar : PubMed/NCBI
|
